Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2014, Article ID 747014, 11 pages
http://dx.doi.org/10.1155/2014/747014
Research Article

PPARα: A Master Regulator of Bilirubin Homeostasis

1Laboratory of Molecular Pharmacology, CHU de Québec Research Centre and Faculty of Pharmacy, Laval University, Québec, QC, Canada G1V 4G2
2Endocrinology and Nephrology, CHU de Québec Research Center, Québec, QC, Canada G1V 4G2
3Institute of Nutraceuticals and Functional Foods (INAF), Laval University, Québec, QC, Canada G1V 0A6

Received 28 February 2014; Revised 11 June 2014; Accepted 11 June 2014; Published 23 July 2014

Academic Editor: Howard P. Glauert

Copyright © 2014 Cyril Bigo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. W. Ryter, J. Alam, and A. M. K. Choi, “Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications,” Physiological Reviews, vol. 86, no. 2, pp. 583–650, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Loboda, A. Jazwa, A. Grochot-Przeczek et al., “Heme oxygenase-1 and the vascular bed: from molecular mechanisms to therapeutic opportunities,” Antioxidants and Redox Signaling, vol. 10, no. 10, pp. 1767–1812, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Brydun, Y. Watari, Y. Yamamoto et al., “Reduced expression of heme oxygenase-1 in patients with coronary atherosclerosis,” Hypertension Research, vol. 30, no. 4, pp. 341–348, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Kaneda, M. Ohno, J. Taguchi et al., “Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 10, pp. 1680–1685, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Jedlitschky, I. Leier, U. Buchholz, J. Hummel-Eisenbeiss, B. Burchell, and D. Keppler, “ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2,” Biochemical Journal, vol. 327, no. 1, pp. 305–310, 1997. View at Google Scholar · View at Scopus
  6. H. A. Schwertner and L. Vítek, “Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin,” Atherosclerosis, vol. 198, no. 1, pp. 1–11, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. P. L. M. Jansen, “Diagnosis and management of Crigler-Najjar syndrome,” European Journal of Pediatrics, vol. 158, supplement 2, pp. S89–S94, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Vítek, M. Jirsa Jr., M. Brodanová et al., “Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels,” Atherosclerosis, vol. 160, no. 2, pp. 449–456, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. J. D. Bancroft, B. Kreamer, and G. R. Gourley, “Gilbert syndrome accelerates development of neonatal jaundice,” Journal of Pediatrics, vol. 132, no. 4, pp. 656–660, 1998. View at Publisher · View at Google Scholar · View at Scopus
  10. C. P. Strassburg, “Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome),” Best Practice and Research: Clinical Gastroenterology, vol. 24, no. 5, pp. 555–571, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. C. Bulmer, H. J. Verkade, and K. H. Wagner, “Bilirubin and beyond: a review of lipid status in Gilbert's syndrome and its relevance to cardiovascular disease protection,” Progress in Lipid Research, vol. 52, no. 2, pp. 193–205, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Novotný and L. Vítek, “Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies,” Experimental Biology and Medicine, vol. 228, no. 5, pp. 568–571, 2003. View at Google Scholar · View at Scopus
  13. T. W. Wu, K. P. Fung, J. Wu, C. Yang, and R. D. Weisel, “Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins,” Biochemical Pharmacology, vol. 51, no. 6, pp. 859–862, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Brites, “Bilirubin injury to neurons and glial cells: new players, novel targets, and newer insights,” Seminars in Perinatology, vol. 35, no. 3, pp. 114–120, 2011. View at Publisher · View at Google Scholar
  15. W. Wahli and L. Michalik, “PPARs at the crossroads of lipid signaling and inflammation,” Trends in Endocrinology and Metabolism, vol. 23, no. 7, pp. 351–363, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. J. D. Tugwood, I. Issemann, R. G. Anderson, K. R. Bundell, W. L. McPheat, and S. Green, “The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene,” The EMBO Journal, vol. 11, no. 2, pp. 433–439, 1992. View at Google Scholar · View at Scopus
  17. S. Mandard, M. Müller, and S. Kersten, “Peroxisome proliferator-activated receptor α target genes,” Cellular and Molecular Life Sciences, vol. 61, no. 4, pp. 393–416, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Lalloyer and B. Staels, “Fibrates, glitazones, and peroxisome proliferator-activated receptors,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 5, pp. 894–899, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Ewang-Emukowhate and A. S. Wierzbicki, “Lipid-lowering agents,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 18, no. 5, pp. 401–411, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Kronke, A. Kadl, E. Ikonomu et al., “Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 6, pp. 1276–1282, 2007. View at Google Scholar
  21. M. Runge-Morris and T. A. Kocarek, “Regulation of sulfotransferase and UDP-Glucuronosyltransferase gene expression by the PPARs,” PPAR Research, vol. 2009, Article ID 728941, 14 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Honda, T. Ikegami, M. Nakamuta et al., “Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid,” Hepatology, vol. 57, no. 5, pp. 1931–1941, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Prueksaritanont, K. M. Richards, Y. Qiu et al., “Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes,” Pharmaceutical Research, vol. 22, no. 1, pp. 71–78, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Bünger, G. J. E. J. Hooiveld, S. Kersten, and M. Müller, “Exploration of PPAR functions by microarray technology—a paradigm for nutrigenomics,” Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids, vol. 1771, no. 8, pp. 1046–1064, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Senekeo-Effenberger, S. Chen, E. Brace-Sinnokrak et al., “Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor α activation,” Drug Metabolism and Disposition, vol. 35, no. 3, pp. 419–427, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Verreault, K. Senekeo-Effenberger, J. Trottier et al., “The liver X-receptor alpha controls hepatic expression of the human bile acid-glucuronidating UGT1A3 enzyme in human cells and transgenic mice,” Hepatology, vol. 44, no. 2, pp. 368–378, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. W.-H. Yin, J.-W. Chen, Y.-H. Chen, and S.-J. Lin, “Fenofibrate modulates HO-1 and ameliorates endothelial expression of cell adhesion molecules in systolic heart failure,” Acta Cardiologica Sinica, vol. 29, no. 3, pp. 251–260, 2013. View at Google Scholar · View at Scopus
  28. H. Lin, C. Yu, C. Jen et al., “Adiponectin-mediated heme oxygenase-1 induction protects against iron-induced liver injury via a PPARα-dependent mechanism,” American Journal of Pathology, vol. 177, no. 4, pp. 1697–1709, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. C. F. Cheng, W.-S. Lian, S.-H. Chen et al., “Protective effects of adiponectin against renal ischemia-reperfusion injury via prostacyclin-PPARα-Heme oxygenase-1 signaling pathway,” Journal of Cellular Physiology, vol. 227, no. 1, pp. 239–249, 2012. View at Publisher · View at Google Scholar
  30. H. Lin, W. Lian, H. Chen, P. Lai, and C. Cheng, “Adiponectin ameliorates iron-overload cardiomyopathy through the PPARα-PGC-1-dependent signaling pathway,” Molecular Pharmacology, vol. 84, no. 2, pp. 275–285, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Chen, T. Chen, and H. Lin, “Pravastatin attenuates carboplatin-induced nephrotoxicity in rodents via peroxisome proliferator-activated receptor α-regulated heme oxygenase-1,” Molecular Pharmacology, vol. 78, no. 1, pp. 36–45, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Du, S. Chang, B. Chen, H. Zhou, and Z. K. Chen, “Adenovirus-mediated heme oxygenase transfer inhibits graft arteriosclerosis in rat aortic transplants,” Transplantation Proceedings, vol. 39, no. 10, pp. 3446–3448, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. N. C. Yang, L. Lu, Y. Kao, and L. Chau, “Heme oxygenase-1 attenuates interleukin-1 β-induced nitric oxide synthase expression in vascular smooth muscle cells,” Journal of Biomedical Science, vol. 11, no. 6, pp. 799–809, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. S.-H. Juan, T.-S. Lee, K.-W. Tseng et al., “Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein e-deficient mice,” Circulation, vol. 104, no. 13, pp. 1519–1525, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. J. A. Araujo, M. Zhang, and F. Yin, “Heme oxygenase-1, oxidation, inflammation, and atherosclerosis,” Frontiers in Pharmacology, vol. 19, no. 3, article 119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Bigo, S. Caron, A. Dallaire-Théroux, and O. Barbier, “Nuclear receptors and endobiotics glucuronidation: the good, the bad, and the UGT,” Drug Metabolism Reviews, vol. 45, no. 1, pp. 34–47, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Turfan, M. Duran, F. Poyraz et al., “Inverse relationship between serum total bilirubin levels and severity of disease in patients with stable coronary artery disease,” Coronary Artery Disease, vol. 24, no. 1, pp. 29–32, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. R. P. F. Dullaart, P. J. W. H. Kappelle, and R. de Vries, “Lower carotid intima media thickness is predicted by higher serum bilirubin in both non-diabetic and Type 2 diabetic subjects,” Clinica Chimica Acta, vol. 414, pp. 161–165, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Huang, P. Huang, H. Leu, T. Wu, S. Lin, and J. Chen, “Serum bilirubin predicts long-term clinical outcomes in patients with cardiac syndrome X,” Heart, vol. 96, no. 15, pp. 1227–1232, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Stocker, Y. Yamamoto, and A. F. McDonagh, “Bilirubin is an antioxidant of possible physiological importance,” Science, vol. 235, no. 4792, pp. 1043–1046, 1987. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Stojanov, A. Stefanovic, G. Dzingalasevic et al., “Total bilirubin in young men and women: association with risk markers for cardiovascular diseases,” Clinical Biochemistry, vol. 46, no. 15, pp. 1516–1519, 2013. View at Publisher · View at Google Scholar
  42. A. Boon, C. L. Hawkins, K. Bisht et al., “Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status in Gilbert syndrome,” Free Radical Biology and Medicine, vol. 52, no. 10, pp. 2120–2127, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Gul, A. K. Kalkan, and H. Uyarel, “Serum bilirubin: a friendly or an enemy against cardiovascular diseases?” Journal of Critical Care, vol. 29, no. 2, pp. 305–306, 2013. View at Publisher · View at Google Scholar
  44. J. Zelenka, L. Muchova, M. Zelenkova et al., “Intracellular accumulation of bilirubin as a defense mechanism against increased oxidative stress,” Biochimie, vol. 94, no. 8, pp. 1821–1827, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Kapitulnik and M. D. Maines, “Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin,” Trends in Pharmacological Sciences, vol. 30, no. 3, pp. 129–137, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Nishioka, H. Hyogo, Y. Numata et al., “A nuclear receptor-mediated choleretic action of fibrates is associated with enhanced canalicular membrane fluidity and transporter activity mediating bile acid-independent bile secretion,” Journal of Atherosclerosis and Thrombosis, vol. 12, no. 4, pp. 211–217, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Kok, V. W. Bloks, H. Wolters et al., “Peroxisome proliferator-activated receptor α (PPARα)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice,” Biochemical Journal, vol. 369, no. 3, pp. 539–547, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. L. M. Aleksunes and C. D. Klaassen, “Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARα-, and Nrf2-null mice,” Drug Metabolism and Disposition, vol. 40, no. 7, pp. 1366–1379, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. D. R. Johnson and C. D. Klaassen, “Regulation of rat multidrug resistance protein 2 by classes of prototypical microsomal enzyme inducers that activate distinct transcription pathways,” Toxicological Sciences, vol. 67, no. 2, pp. 182–189, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. J. M. Maher, X. Cheng, A. L. Slitt, M. Z. Dieter, and C. D. Klaassen, “Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver,” Drug Metabolism and Disposition, vol. 33, no. 7, pp. 956–962, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Heydel, P. Garnier, P. Faure, and Y. Artur, “Ciprofibrate regulation of rat hepatic bilirubin glucuronidation and UDP-glucuronosyltransferases expression,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 37, no. 4, pp. 233–240, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. F. Eghbalian, A. Pourhossein, and H. Zandevakili, “Effect of clofibrate in non-hemolytic indirect hyperbilirubinemia in full term neonates,” Indian Journal of Pediatrics, vol. 74, no. 11, pp. 1003–1006, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. S. H. Sakha, M. Gharehbaghi, and M. Rahbani, “The effect of clofibrate with phototherapy in late pre-term newborns with non-hemolytic jaundice,” Indian Journal of Medical Sciences, vol. 63, no. 5, pp. 174–179, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Gholitabar, H. McGuire, J. Rennie, D. Manning, and R. Lai, “Clofibrate in combination with phototherapy for unconjugated neonatal hyperbilirubinaemia,” Cochrane Database of Systematic Reviews, vol. 12, Article ID CD009017, 2012. View at Google Scholar · View at Scopus
  55. P. K. Jaikrishan and A. Narang, “Gemfibrozil in late preterm and term neonates with moderate jaundice: a randomized controlled trial,” Indian Pediatrics, vol. 46, no. 12, pp. 1063–1069, 2009. View at Google Scholar · View at Scopus